StockData

Can-Fite BioPharma vs Scienture

CANF and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CANF and SCNX compare

Scienture scores higher on the StockData Score (3 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCANFSCNX
Size and price
Market cap–$123M
Share price$1.56$2.99
Change, 1 year−79.0%−82.2%
Change, 5 years−99.4%−99.8%
Beta (5Y)1.441.07
Employees58
StockData Score
Total score13 (better)
Valuation score01 (better)
Growth score00
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/B–1.9×
Growth
Revenue growth (TTM)−39.9%–
Revenue growth, 5Y average−11.9% (better)−52.1%
Profitability
Operating margin−2457%–
Net margin−2427%–
FCF margin−2210%–
Return on equity−217%−53.5% (better)
Return on invested capital–−47.3%
Financial health
Interest coverage−35.0×−13.1× (better)
Current ratio3.60 (better)3.04
Altman Z-score–0.31
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions1.9%–
Held by insiders0.00%16.6%
Short interest, % of float–0.34%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.